HMGB1: A Promising Therapeutic Target for Prostate Cancer.
HMGB1: A Promising Therapeutic Target for Prostate Cancer.
复制标题
DOI：
10.1155/2013/157103
复制
发表时间：
2013
期刊：
影响因子：
4.2
通讯作者：
Kajdacsy-Balla A
中科院分区：
文献类型：
--
作者：
Gnanasekar M;Kalyanasundaram R;Zheng G;Chen A;Bosland MC;Kajdacsy-Balla A
高迁移率族蛋白1(HMGB1)是几十年前发现的一种染色质结合蛋白。现在越来越明显的是，HMGB1在几种疾病中发挥着重要作用，如动脉粥样硬化、糖尿病、关节炎、败血症和癌症。令人感兴趣的是，HMGB1的放松管制如何会导致无数的疾病状况。有趣的是，HMGB1参与了肿瘤进展过程中的细胞增殖、血管生成和转移。此外，HMGB1已被证明发挥细胞内和细胞外的功能，激活关键的致癌信号通路。本文重点阐述了HMGB1在前列腺癌发生发展中的作用，并强调了HMGB1作为前列腺癌治疗的关键靶点的潜力。
High mobility group box 1 (HMGB1) was originally discovered as a chromatin-binding protein several decades ago. It is now increasingly evident that HMGB1 plays a major role in several disease conditions such as atherosclerosis, diabetes, arthritis, sepsis, and cancer. It is intriguing how deregulation of HMGB1 can result in a myriad of disease conditions. Interestingly, HMGB1 is involved in cell proliferation, angiogenesis, and metastasis during cancer progression. Furthermore, HMGB1 has been demonstrated to exert intracellular and extracellular functions, activating key oncogenic signaling pathways. This paper focuses on the role of HMGB1 in prostate cancer development and highlights the potential of HMGB1 to serve as a key target for prostate cancer treatment.